#mucormycosis market analysis

[blogaarti]

Mucormycosis Market Analysis, Market Size, In-Depth Insights, Growth and Forecast 2025

Mucormycosis is a rare and potentially fatal fungal disease that has burst into the limelight recently. The infection is caused by a group of fungi known as mucormycetes and has a high fatality rate. As per U.S. Center for Disease Control and Prevention data, the disease targets the brain, sinuses, and lungs, and is particularly problematic for immune-compromised patients afflicted with HIV, cancer, or diabetes. Mucormycosis can even progress to disfigurement of the eyes, nose, or face, permanent blindness, or invasive brain infection, making it imperative to tackle in the earliest stages of detection.

For More Insights into the Market, Get Sample Copy of this Report:

https://www.fairfieldmarketresearch.com/report/mucormycosis-market/

Lethal Combination of COVID-19 and Steroid Abuse Allows Mucormycosis to Run Rampant in India

The second wave of COVID-19 in India has led to an uptick of mucormycosis cases in the subcontinent. It is likely that mucormycosis is affecting patients due to the excess prescription of immunosuppressant and corticosteroid drugs. Diabetics who contract COVID-19 or those receiving concentrated, humidified oxygen for extended durations are at great risk. For e.g. – Sion hospital in Mumbai has reported a four-fold increase in mucormycosis cases in March 2021, compared to the same period last year. In 2021, India alone accounts for approx. half of global mucormycosis cases. A prominent restraint to overcome in the APAC mucormycosis market is an overall lack of market access. In an Indian study, a quarter of patients were discharged from hospitals before any treatment as they could not afford the medical costs or the medical prognosis was incorrect.

Government Encouragement to Anti-infective Drug Industry Allows Europe to Lead Mucormycosis Market

The pervasiveness of diabetes mellitus has slowly risen in Europe and is now approaching double digits. Furthermore, government initiatives to boost the anti-infective drugs industry is projected to benefit the mucormycosis market in the region. The European Confederation of Medical Mycology (ECCM) is spearheading efforts by drafting global guidelines for the diagnosis and management of mucormycosis.

In Order to place the Purchase Query Click Here: sales@fairfieldmarketresearch.com

Coagulopathy Challenges Fail to Prevent Tissue Biopsy Segment Dominating Mucorymycosis Market

The primary diagnostic test in the mucormycosis market is tissue biopsy, challenges in culturing mucor notwithstanding. Different types of rapid laboratory screening tests comprise Calcofluor White Stain and KOH mount. The benefits of tissue biopsy largely outweigh its risks in cases of location inaccessibility or coagulopathy. Other forms of imaging techniques widely deployed in the mucormycosis market include computed tomography (CT) scans and magnetic resonance imaging (MRI). It is essential to treat mucormycosis as early as possible with amphotericin B, isavuconazole, or Posaconazole – either administered intravenously or orally. The gold standard for treating invasive mucormycosis has long been amphotericin B, while surgical debridement is key in mucormycosis management. Additional options in the mucormycosis market consist of statins, deferasirox, caspofungin, hyperbaric oxygen, and aspirin.

Prevalence of Diabetes Globally Makes Rhinocerebral Mucormycosis A Major Burden

The five types of infections to be tackled in the mucormycosis market are rhinocerebral (sinus and brain), pulmonary (lung), gastrointestinal, cutaneous (skin), and disseminated mucormycosis. Rhinocerebral mucormycosis is most common in those who have undergone a kidney transplant or have diabetes. Conversely, pulmonary mucormycosis rears its ugly head in cancer patients, or in those who have successfully undergone stem cell transplants.

Browse Our Latest Reports: https://www.fairfieldmarketresearch.com/shop/

About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

[sapanas]

Mucormycosis market research report analysis by diagnosis (Rhizopus, Rhizomucor, Cunninghamella, Apophysomyces, Saksenaea, Lichtheimia, Mucor), by diagnosis (CT, MRI, tissue biopsy), by treatment (surgery, antifungal), by end user – Global forecast till 2023

Mucormycosis Market – Overview

The rise in the causative factor for mucormycosis and poor detection rate has contributed to the development of the market. Reports that gauge the healthcare industry have been made available by Market Research Future which creates reports on several industry verticals that review the market growth and prospects. The market is expected to garner a CAGR of 7.3% approx, in the upcoming period.

[iccpl]

Media Mapping Survey by Top PR Agencies in India for Q1-FY21-22

This survey report provides information obtained through media analysis, regarding the news trends across major publications in the country. This survey report will pay particular attention to the news trends in the first quarter of FY2021-22 when the country was reeling under heavy pandemics. These observations do have limitations that will be noted and are based on a total number of stories categorised by different sectors. Not only India, but the entire world is experiencing a devastating wave of COVID-19. The spread of COVID-19 in India was initially characterized by fewer cases and lower case fatality rates compared with numbers in many developed countries, primarily due to a stringent lockdown and a demographic dividend. However, economic constraints forced a staggered lockdown exit strategy, resulting in a spike in COVID-19 cases. This factor, coupled with low spending on health as a percentage of gross domestic product (GDP), created mayhem because of inadequate numbers of hospital beds and ventilators and a lack of medical personnel, especially in the public health sector. Nevertheless, technological advances, supported by a strong research base, helped contain the damage resulting from the pandemic. In the first ten days of May, India’s reported count of COVID-19 deaths was nearly 40,000, roughly accounting for a third of deaths worldwide during this period. The media ecosystem continues to be challenging this year – and that was before the pandemic. To inform the citizens during these uncertain times, newsrooms and media houses across the country have made pandemic coverage a priority. While there is an abundance of news to be reported on the global pandemic, the esteemed media houses of the country pointed out several other news trends to keep people educated and aware.

THE INDIAN MEDIA

“FREE PRESS IS ESSENTIAL TO FREE SOCIETY”

The Indian Media Industry is one of the world’s most diverse and vibrant in addition to being largely free and fair. The Indian media landscape has changed significantly over the last one decade. With the advancement in technology, the Indian media industry has been burgeoning like never before and expanded its reach, in terms of the number of outlets, whether in television, radio, print or digital.

At this hour of the global pandemic, media has successfully played the role of a watchdog of the government functionaries and has also aided in participatory communication in raising major issues faced by the citizens of the country. Several media platforms across the country kept providing credible news and information to the citizens of the country when they most needed it without letting fear affect them amid COVID-19. The onset of the global pandemic and ensuing lockdown has dealt a severe blow to the Indian economy. It is being reported that the Indian Media & Entertainment sector, which saw a contraction of around 24 per cent at Rs 1.38 lakh crore in the pandemic-struck 2020, is expected to log growth this year and double its revenue to Rs 2.68 lakh crore by 2025.

Print newspapers in India have been seeing a significant surge in revenue, making it the largest global market for the industry. The most popular daily in the country is “The Times of India” that had the highest average readership in 2017. India’s print industry is to be able to retain their audiences through digital platforms, while still maintaining enough advertising and subscription revenue to continue different editions.

TREND ANALYSIS OF COVID-19 OUTBREAK IN INDIA

More than 15 countries including the US, Russia, France and the United Kingdom rushed critical emergency use equipment to enable India counter the COVID-19’s deadly second wave. Ministry of External Affairs announced that several countries are sending hundreds of oxygen concentrators, respirators and large quantities of liquid oxygen to help India at this hour of the pandemic. The Delhi High Court announced that it will take up court proceedings through virtual mode from April 9 to April 23. India became the first country in the world to report over 4 lakh new cases on April 30, 2021. It was being speculated that the COVID-19 wave that plunged India into the world’s biggest health crisis has the potential to worsen in the coming weeks, with some research models projecting that the death toll could more than double from current levels. Several states of the country introduced lockdowns, although Prime Minister Narendra Modi resisted a national effort after one imposed by the Central government last year fueled a humanitarian crisis with migrant workers fleeing the cities on foot and in some cases bringing the virus with them. A devastating second wave of coronavirus in India has seen hospitals and crematoriums overwhelmed and widespread shortages of oxygen and medicines. Hospitals across India are also experiencing oxygen shortages, with some forced to put up signs warning of a lack of supplies. War of words erupted between the Central government and several state governments such as Delhi & Maharashtra government over oxygen supply.

Fitch group company (India Ratings) said “the second wave of COVID-19 infections will be less disruptive than the first wave for the business environment as corporates are better prepared”. But it was being reported that smaller businesses including micro, small and medium enterprises are laying off more employees as demand and sales have plummeted due to localised lockdowns implemented by the state governments. The Centre for Monitoring Indian Economy, recently said that “the unemployment rate in the country has touched a four-month high as over 70 lakh jobs have been impacted.” Amid the concerns regarding shortage of COVID-19 vaccines in the national capital, the Delhi government recently stated that “the vaccination of the 18-44 age group remained suspended for the fifth consecutive day” and further informed that there is no COVAXIN stock available for any age group.

AAP MLA Atishi said “Delhi has already shut 235 of the 368 inoculation centres for this category due to a shortage of vaccines.” Few other states including Maharashtra suspended vaccination for 18-44 age group, citing shortage of doses. Amid the COVID-19 outbreak in the country, cases of Mucormycosis (Black Fungus) have emerged in patients who were in the recovery phase of the disease. Hundreds of corpses were also found floating in the Ganga river or buried in the sand of its banks in the northern state of Uttar Pradesh, fearing they were COVID-19 infected.

Prime Minister during his latest address to the nation said "The Centre is taking back total control of vaccination now, will be implemented in next two weeks. The Centre will give free vaccines to states for all above 18. From 21 June, the Centre will provide free vaccines to states." Prime Minister also announced free ration for the poor under Prime Minister Garib Kalyan Yojana till Diwali.

As the second wave of coronavirus in the country continues to slow down, several states have started easing the strict restrictions which were imposed to check the spread of the deadly virus. Delhi resumed the Metro train services with 50 per cent seating capacity.

Malls, markets and market complexes were allowed to open between 10 am to 8 pm on odd-even basis in accordance with their shop numbers. Private offices also opened up with 50 per cent manpower. In Uttar Pradesh, the curfew continues to remain in districts that have more than 600 actives cases. With states unlocking across the country and the Delta variant still around, health experts are continuously stressing on the need to re-open with a robust vaccination strategy and COVID appropriate behaviour.

The Drugs Controller General of India (DGCA) has granted its nod to Indian pharmaceutical giant Cipla to import Moderna’s COVID-19 vaccine for restricted emergency use in the country. The Directorate General of Civil Aviation (DGCA) extended the restrictions on scheduled international passenger flights to and from India extended till July 31st, 2021. DGCA also stated “However, international scheduled flights may be allowed on selected routes by the competent authority on a case-to-case basis.”

US President Joe Biden and house unanimously passed a resolution recognizing the devastating impact of COVID-19 in India and expressing the sense of the House of Representatives to urgently facilitate assistance. Indian Council of Medical Research (ICMR) recently stated that India crossed the milestone of conducting 400 million tests for COVID-19 since the pandemic began, with the last 50 million tests being conducted over the last 24 days. The United States’ National Institutes of Health reported that India’s first indigenously developed COVID-19 vaccine Covaxin is able to effectively neutralise the Alpha and Delta variants of SARS-CoV-2. Read more on: https://www.iccpl.in

[karishmamulani]

Global Mucormycosis Market Size Estimated High Growth During the Period 2021-2028

Global Mucormycosis Market Size Estimated High Growth During the Period 2021-2028

The global mucormycosis market size is expected to reach USD 616.1 million by 2028 according to a new study by Polaris Market Research. The report “Mucormycosis Market Share, Size, Trends, Industry Analysis Report; By Diagnosis (Computed Tomography, MRI, Tissue Biopsy); By Treatment (Surgery, Antifungal Drugs, Amphotericin B Therapy, Others); By End-Use; By Region; Segment Forecast, 2021 –…

[rajputdishank20-blog]

Antifungal Drugs Market By Drug Classes, By Indications, By Dosage Forms And Regions – Global Industry Analysis, Growth, Share, Size, Trends And Forecast 2020 – 2026

The global antifungal drugs market is projected to reach USD 13,500 million by 2026, expanding at a CAGR of 3.2% during the forecast period, 2020 – 2026. The growth of the market is attributed to the increasing fungal infections. 

Antifungal drugs are used to treat fungal infections. These fungal infections consist of soggy, unhygienic, and unclean environments in which fungus thrive. Fungi multiply by spreading microscopic spores. They infect the surface of the body such as skin or are inhaled and subsequently lead to fungal infections. Fungal infections can harm superficial as well as systemic parts of the body, such as eyes, skin, mouth, and vagina. Systemic fungal infections result from inhalation or ingestion of spores and lead to various fungal diseases such as fungal pneumonia, meningitis, candidiasis, and mucormycosis. Fungal infections are usually non-lethal but can result in death in rare cases.

Market Trends, Drivers, Restraints, and Opportunities:

Increasing demand for OTC antifungal drugs, growing cases of fungal infections, and rising R&D in healthcare sector on fungal treatment are driving the growth of the market.

Expiration of patents of branded drugs and availability of alternate treatment are restraining the growth of the market.

Public-private partnership agreements in the pharmaceutical sector for R&D of novel antifungal treatment is estimated to create growth opportunities in the near future.

An international public-private partnership, CARB-X, is anticipated to provide around USD 350 million during the forecast period to boost the R & D pipeline.

Read More: https://dataintelo.com/report/antifungal-drugs-market/

[shristipbi]

Antifungal Drugs Market Growth, Market Insights and Forecast to 2025

The global antifungal drugs market was valued at US$ XX Mn in 2018 and increasing at a significant growth rate over the forecast years due to increase in the prevalence of fungal diseases such as aspergillosis, candidiasis, dermatophytosis and others. For instance, according to Center for Diseases Control and Prevention, approximately 1 Mn affected with cryptococcal meningitis, a brain infection caused by fungus around the globe. Moreover, surge in incidence of hospital acquired infection, increase in the R&D expenditure for the development of newer antifungal drugs, unhygienic environments in underdeveloped countries, and rise in healthcare expenditure are propel the global antifungal drugs market over the forecast years. However, alternative treatment procedures for the fungal infections, patent expiry of branded drugs, and entry of generics into market are hamper the growth of antifungal drugs market over the forecast timeframe

Global antifungal drugs market segmented on the basis of drug class, disease type, route of administration, distribution channel, and region

 For request sample: https://www.precisionbusinessinsights.com/request-sample?product_id=15770

 Azoles Dominate the Global Antifungal Drugs Market

Based on the drug class, global antifungal drugs market segmented into azoles, echinocandins, polyenes, allylamines, and others. Among all the drug classes, azoles dominated the global antifungal drugs market in 2018 and the same trend is expected over the forecast years owing to launch of newer therapeutics into the market. For instance, in November 2017, Pfizer partnered with Basilea to launch antifungal drug Cresemba (Isavuconazole) used in the treatment of mucormycosis infection in adults. Moreover, increase in the awareness among the population about antifungal drugs also surge the global antifungal drugs market over the future years.

North America Leads the Global Antifungal Drugs market

PBI’s global antifungal drugs market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America accounted for larger revenue share through 2014-2018 and expected to dominate over 2019-2025 owing to surge in the incidence of fungal diseases in U.S. and Canada. For instance, according to CDC, approximately 25,000 people diagnosed with candidemia each year. Moreover, favorable reimbursement policies, increase in the R&D activities for the development of newer therapeutics, and surge in healthcare expenditure are bolster the market over the forecast years. Asia Pacific antifungal drugs market projected to exhibit significant growth due to large patient pool, rapid growth in population in India and China, and launch of generics in the regions.

Launch of newer products, frequent product approvals, and strategic alliances are the key strategies adopted by market players

Global antifungal drugs market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For instance. In December 2016, Dr. Reddy’s launched Nystatin and Triamcinolone Acetonide Cream, a generic antifungal product for the treatment of cutaneous candidiasis.

Key player’s profiles in the report are AbbVie, Inc., Merck & Co. Inc., Amgen, Inc., Novartis AG, Sanofi S.A., Eisai Co., Ltd., GlaxoSmithKline plc, Dr. Reddy’s Laboratories, Enzon Pharmaceuticals, Inc., and Basilea Pharmaceuticals, Ltd.,

Precision Business Insights (PBI) in its report titled “Global Antifungal Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

Detailed Segmentation

By Drug Class

o    Azoles

o    Polyenes

o    Echinocandins

o    Allylamines

o    Others

Disease Type

o    Aspergillosis

o    Candidiasis

o    Dermatophytosis

o    Others

Route of Administration

o    Oral

o    Parenteral

o    Topical

By Distribution Channel

o    Hospital Pharmacies

o    Retail Pharmacies

o    Online Pharmacies

Geography

o     North America

·         U.S

·         Canada

o     Europe

·         Germany

·         France

·         U.K

·         Italy

·         Spain

·         Russia

·         Poland

·         Rest of Europe

o     Asia-Pacific

·         Japan

·         China

·         India

·         Australia & New Zealand

·         ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)

·         South Korea

·         Rest of Asia-Pacific

o     Latin America

·         Brazil

·         Mexico

·         Argentina

·         Rest of Latin America

o     Middle East and Africa (MEA)

·         Gulf Cooperation Council (GCC) Countries

·         Israel

·         South Africa

·         Rest of MEA

  For more information: https://www.precisionbusinessinsights.com/market-reports/global-anti-fungal-drugs-market/

 Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customized market research services based on our client needs.

 Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

[sapanas]

Mucormycosis Market Research Report By 2023 | Global Industry Trends, Growth Rate, Size, Analysis

Market Research Future has added a report titled “Mucormycosis Market Research Report- Global Forecast till 2023” to its offering.

Market Scenario:

Mucormycosis (zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. Moreover, inhaling fungal spores from the air can affect the lungs and sinuses, the fungus also invades the skin through wounds such as cut, scrape, burn, or other type of skin trauma. There are approximately 1.5 million different species of fungi on the earth, however, only around 300 are responsible for causing diseases and infections in humans. Fungal infection may affect anyone, but they are most common in people with weakened immune systems and can occur in nearly any part of the body. Risk factors for developing mucormycosis include uncontrolled diabetes, cancer, organ transplant, neutropenia, skin trauma such as cuts, scrapes, punctures, or burns.  

Get Free Sample of This Report @ https://www.marketresearchfuture.com/sample_request/5440

These infections need to be treated with prescribed antifungal medication, usually amphotericin B, posaconazole or isavuconazole. Amphotericin B, posaconazole, and isavuconazole are medications given intravenously. Furthermore, posaconazole and isavuconazole can also be administered orally. Often, mucormycosis requires surgery to remove the infected tissue.

The prognosis of mucormycosis is usually poor. It depends on various factors such as the overall health of the patient and ability to respond to treatments, the speed of diagnosis, and treatment provided. For instance, the mortality rate with rhinocerebral and GI mucormycosis is about 85% while the mortality rate for patients with other types of mucormycosis is about 50%. Patients who survive this infection often end up having disabilities such as blindness, limb loss, organ dysfunctions among others.

The market growth is mainly driven by increasing prevalence of fungal infections, availability of wide range of products, and rising incident of immunological diseases. Moreover, increasing awareness about fungal infection and increasing government support for research & development have fuelled the market growth. However, side effects of the treatment and presence of misbranded and spurious drugs may slow the growth of the market. There are a number of medicines available in the market for the treatment of fungal infections such as oral and intravenous medicines, creams, sprays, shampoos, solutions, and pessaries.

Rising incidence of immunological diseases and availability of a wide range of products has driven the growth of the global mucormycosis market. Furthermore, rising geriatric population, increasing government support, and increasing healthcare expenditure have fueled the growth of the market. However, side effects of the drugs and presence of misbranded drugs may hinder the growth of the market.

The global market for mucormycosis is expected to grow at a CAGR of approximately 7.3% during the forecast period, 2017-2023.

Key Players:

The Global Mucormycosis Market key players are Abbott Laboratories (U.S.), Biocon Limited (India),  Cadila Pharmaceuticals Limited (India), Novartis AG (Switerzland), F. Hoffman La Roche (Switerzland),   Merck Sharp and Dohme (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.),  Bayer AG (Germany), Lonza Group (Switerzland), Sanofi (France), Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Gilead Sciences (U.S.), and others

Segmentation:

The mucormycosis is segmented on the basis of species, diagnosis, treatment, and end-users.

On the basis of the species, the market is segmented into Rhizopus, Rhizomucor, Cunninghamella, Apophysomyces, Saksenaea, Lichtheimia (formerly Absidia), and Mucor, and others

On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), tissue biopsy, and others.

On the basis of the treatment, the market is segmented into surgery, antifungal drugs, amphotericin B therapy, and others. The antifungal drugs is further categorized into posaconazole, isavuconazole, voriconazole, fluconazole, and flucytosine, and others.

On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.

Regional Analysis:                    

The Global Mucormycosis Market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas dominate the global mucormycosis market owing to a well-developed healthcare sector and huge patient population for mucormycosis. Many antifungal drugs have lost their patients during the last few years such as Terbinafine products like Lamisil lost their patient in 2017. As there is limited oral preparation in the market, development and licensing of new drugs in the market is the huge opportunity for the development of the market during the forecasted period.

Europe is the second largest market for the global mucormycosis owing to the advancements in the technology of the surgical devices along with the rising occurrence of fungal infections among the patients. The European government introduced incentives to help simplify the improvement of anti-infective drugs and dropping the risk and cost of manufacturers. Some other factors driving the market include the growing percentage of diabetes mellitus population mainly in the developed countries of Europe. The average diabetes prevalence rate in Europe is 8.6% of the adult population.

Asia Pacific is the fastest growing region for antifungal treatment due to increasing prevalence of HIV, and huge untapped growth opportunities for the development of the market. Every year, approximately 7.1% of the Korean population receives treatment for fungal diseases. Therefore, further research is needed to understand and monitor the prevalence of mycoses to establish management policies to reduce the burden of fungal diseases.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Treatment Trends & Assessment

Chapter 5. Market Factor Analysis

… Continued!

Price: $4450 (Single User)

Pages: 120

Browse Full Reports @ https://www.marketresearchfuture.com/reports/mucormycosis-market-5440

[karishmamulani]

Mucormycosis Market 2021 In-Depth Industry Analysis By Types, Applications

Mucormycosis Market 2021 In-Depth Industry Analysis By Types, Applications

The report “Global Mucormycosis Market  2028” from PMR Market Research includes data and information about market structure and size. The purpose of this research is to give market knowledge and strategic insights to assist in decision making, making informed investment decisions, and identifying potential growth opportunities. The global mucormycosis market size is expected to reach USD 616.1…

[ashukalbande21-blog]

Mucormycosis Market 2019 – Global Industry Size, Share, Analysis, Trend & Future Strategic Planning

Market Research Future has added a report titled “Mucormycosis Market Research Report- Global Forecast till 2023” to its offering.

Market Scenario:

Mucormycosis (zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. Moreover, inhaling fungal spores from the air can affect the lungs and sinuses, the fungus also invades the skin through wounds such as cut, scrape, burn, or other type of skin trauma. There are approximately 1.5 million different species of fungi on the earth, however, only around 300 are responsible for causing diseases and infections in humans. Fungal infection may affect anyone, but they are most common in people with weakened immune systems and can occur in nearly any part of the body. Risk factors for developing mucormycosis include uncontrolled diabetes, cancer, organ transplant, neutropenia, skin trauma such as cuts, scrapes, punctures, or burns.  

Get Premium Copy @ https://www.marketresearchfuture.com/sample_request/5440

These infections need to be treated with prescribed antifungal medication, usually amphotericin B, posaconazole or isavuconazole. Amphotericin B, posaconazole, and isavuconazole are medications given intravenously. Furthermore, posaconazole and isavuconazole can also be administered orally. Often, mucormycosis requires surgery to remove the infected tissue.

The prognosis of mucormycosis is usually poor. It depends on various factors such as the overall health of the patient and ability to respond to treatments, the speed of diagnosis, and treatment provided. For instance, the mortality rate with rhinocerebral and GI mucormycosis is about 85% while the mortality rate for patients with other types of mucormycosis is about 50%. Patients who survive this infection often end up having disabilities such as blindness, limb loss, organ dysfunctions among others.

The market growth is mainly driven by increasing prevalence of fungal infections, availability of wide range of products, and rising incident of immunological diseases. Moreover, increasing awareness about fungal infection and increasing government support for research & development have fuelled the market growth. However, side effects of the treatment and presence of misbranded and spurious drugs may slow the growth of the market. There are a number of medicines available in the market for the treatment of fungal infections such as oral and intravenous medicines, creams, sprays, shampoos, solutions, and pessaries.

Rising incidence of immunological diseases and availability of a wide range of products has driven the growth of the global mucormycosis market. Furthermore, rising geriatric population, increasing government support, and increasing healthcare expenditure have fueled the growth of the market. However, side effects of the drugs and presence of misbranded drugs may hinder the growth of the market.

The global market for mucormycosis is expected to grow at a CAGR of approximately 7.3% during the forecast period, 2017-2023.

Key Players:

The Global Mucormycosis Market key players are Abbott Laboratories (U.S.), Biocon Limited (India),  Cadila Pharmaceuticals Limited (India), Novartis AG (Switerzland), F. Hoffman La Roche (Switerzland),   Merck Sharp and Dohme (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.),  Bayer AG (Germany), Lonza Group (Switerzland), Sanofi (France), Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Gilead Sciences (U.S.), and others

Segmentation:

The mucormycosis is segmented on the basis of species, diagnosis, treatment, and end-users.

On the basis of the species, the market is segmented into Rhizopus, Rhizomucor, Cunninghamella, Apophysomyces, Saksenaea, Lichtheimia (formerly Absidia), and Mucor, and others

On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), tissue biopsy, and others.

On the basis of the treatment, the market is segmented into surgery, antifungal drugs, amphotericin B therapy, and others. The antifungal drugs is further categorized into posaconazole, isavuconazole, voriconazole, fluconazole, and flucytosine, and others.

On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.

Browse Full Reports @ https://www.marketresearchfuture.com/reports/mucormycosis-market-5440

Regional Analysis:                    

The Global Mucormycosis Market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas dominate the global mucormycosis market owing to a well-developed healthcare sector and huge patient population for mucormycosis. Many antifungal drugs have lost their patients during the last few years such as Terbinafine products like Lamisil lost their patient in 2017. As there is limited oral preparation in the market, development and licensing of new drugs in the market is the huge opportunity for the development of the market during the forecasted period.

Europe is the second largest market for the global mucormycosis owing to the advancements in the technology of the surgical devices along with the rising occurrence of fungal infections among the patients. The European government introduced incentives to help simplify the improvement of anti-infective drugs and dropping the risk and cost of manufacturers. Some other factors driving the market include the growing percentage of diabetes mellitus population mainly in the developed countries of Europe. The average diabetes prevalence rate in Europe is 8.6% of the adult population.

Asia Pacific is the fastest growing region for antifungal treatment due to increasing prevalence of HIV, and huge untapped growth opportunities for the development of the market. Every year, approximately 7.1% of the Korean population receives treatment for fungal diseases. Therefore, further research is needed to understand and monitor the prevalence of mycoses to establish management policies to reduce the burden of fungal diseases.

[infraindia]

Mucormycosis Market Size, Growth and Foresight to 2023: illuminated by new report

Market Scenario

The Global Microarray Analysis Market is expected to witness tremendous growth during the forecast period. Microarray analysis is a molecular biology technique that uses microchips containing attached short DNA segments which are used for the analysis of gene expression on a large scale. This enables medical practitioners to decide the most effective treatment for individual patients. Microarray analysis can be used in various experiments such as epigenetics, genotyping, biomarker profiling, translation profiling, pathway identification mutations, and gene expression profiling. The techniques allow the scientists to analyze several genes at a time with accurate results. The rising prevalence of genetic disorders, increased focus on drug discovery and development, and rising demand for personalized medicines are driving the market growth.  According to the Genetic Disorders UK 2017, every year approximately 30,000 new born children are diagnosed with genetic diseases. Microarray analysis helps in understanding the gene patterns in different types of tumors. They are also used for detection of cancer biomarker and also for its research. Hence the rising prevalence of cancer and increasing investments for cancer research can drive the market growth.

However, factors such as high costs of diagnosis, contamination, and inaccurate results are expected to hinder the market growth during the forecast period

Get Premium Sample Copy @ https://www.marketresearchfuture.com/sample_request/896

Key players

Some of the key players for the Global Microarray Analysis Market are Affymetrix, Inc., Agilent Technologies, Inc., Sequenom, Inc., Roche NimbleGen, Illumnia, Inc., and Applied Microarrays. Other companies operating in the global microarrays market are biomerieux SA, Discerna, Gyros AB, Luminex Corporation, NextGen Sciences, PLC, Thermo Fisher Scientific, and ProteoGenix.

Segmentation

The Global Microarray Analysis Market is segmented on the basis of type, application, product type, and end-user.  The Global Microarray Analysis Market, by type, is segmented into DNA microarrays, protein microarrays, tissue microarrays, cellular microarrays, chemical compound microarrays, glycan arrays, and phenotype microarrays. The application segment is segmented into research, genotyping, forensic analysis, proteomics, genomics, disease diagnosis, drug discovery, and toxicological research. The product type segment is further sub-segmented into reagents, primers, buffers, DNA chips, reagent kits, and instruments. The instrument category consists of scanner, hybridization oven, Multi-Channel (MC) instrument, target preparation instrument, slide imprinters, centrifuge, and others. On the basis of end-user, the market is categorized into pharmaceuticals, biotechnology, hospitals and clinics, diagnostic centers, academic and research institutes, and ambulatory care centers.

On the basis of region, the Global Microarray Analysis Market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Regional Market Summary

The Microarray Analysis Market is dominated by the Americas owing to the adoption of advanced technology for diagnosis, awareness among people for better diagnostics, and high investments in research. The National Cancer Institute received USD 5.665 billion from the States Congress for cancer research programs in 2018.

It is estimated that Europe was the second largest in the Global Microarray Analysis Market. The rising focus on drug discovery, personalized medicines, and targeted therapy are driving the growth of the market in this region. In November 2016, over 30 European and international members along with the European Commission established an initiative called the International Consortium for Personalized Medicine, or "ICPerMed" to establish Europe as a global leader in personalized medicine research. Thus, the increasing research in personalized medicines serves favorable backgrounds for the market to grow in this region.

The Microarray Analysis Market in Asia-Pacific is expected to witness growth owing to rising prevalence of genetic disorders, growing awareness among the people, and government initiatives.  According to Alzheimer's Disease International, in 2015, 23 million people in the Asia-Pacific region had dementia, and by 2050 the number is expected to rise to 71 million.

The Middle East and Africa holds the least share in the Global Microarray Analysis Market due to low funding in medical and health research. However, the rising prevalence of genetic diseases and increasing healthcare spending favor the market growth in this region.

Reports Enquiry @ https://www.marketresearchfuture.com/enquiry/896

[healthcaretrends-blog]

Aspergillosis Treatment Market Dynamics And Trends

Aspergillosis is a group of diseases that occur from aspergillus infection. Aspergillus is a fungus whose spores are present in the air, but does not normally cause illness. Individuals with damaged lungs, sensitive immune system, and allergies are more prone to Aspergillus induced infection. Common Aspergillus infections include invasive Aspergillosis, non-invasive Allergic Pulmonary Aspergillosis (ABPA), and Chronic Pulmonary and Aspergilloma (CPA). Invasive aspergillosis is uncommon and occurs primarily in immunocompromised people. Chronic pulmonary aspergillosis is rare pulmonary disease, which increases symptoms of respiratory disorders such as asthma. According to a study published by European Respiratory Society (ERS) publications, in 2015, CPA is estimated to affect nearly 240,000 people in Europe. The most common form of CPA is Chronic Cavitary Pulmonary Aspergillosis (CCPA), which if left untreated can develop chronic fibrosing pulmonary aspergillosis. According to a statistics published by Centers for Disease Control and prevention, (CDC) an estimated 10% of individuals with asthma or cystic fibrosis experience an allergic reaction to aspergillus. ABPA is estimated to affect 2-15% of patients with cystic fibrosis and around 2% of all asthma patients.

Get The Holistic SAMPLE :

https://www.coherentmarketinsights.com/insight/request-sample/1587

Aspergillosis Treatment Market Dynamics

Increasing prevalence of Aspergillosis and favorable government regulations are the major factors driving growth of the Aspergillosis treatment market. According to a study published in Journal of Fungi 2016, CPA is estimated to affect nearly three million people globally making it major health problem resulting in mortality and morbidity. Aspergillosis infection can be treated with antifungal and corticosteroids drugs. Corticosteroid drugs are prescribed for allergic bronchopulmonary aspergillosis treatment. These drugs reduce inflammation and lowers respiratory symptoms such as coughing and wheezing. Some of the most frequently used drugs are methylprednisolone, prednisolone and prednisone. The U.S. Food & Drug Administration (FDA) approved various drugs for Aspergillosis infection treatment. For instance, in 2015, the U.S. FDA approved Isavuconazonium (Astellas Pharma), a prodrug form of Isavuconazole. Antifungal drugs are majorly used to treat invasive pulmonary Aspergillosis. Voriconazole, an antifungal drug is widely used due to less side effects and more effectiveness in comparison to other drugs. Itraconazole or Amphotericin B also treat the infection effectively. Caspofungin is used to treat infection, resistant to the other antifungals. Furthermore, antifungal drugs are sometimes used in combination with corticosteroids for treating ABPA. Surgeries may be required in some cases where aspergillomas are present leading to serious problems such as excessive bleeding. Antifungal drugs are generally not effective against aspergillomas, therefore surgery such as embolization is recommended. An aspergilloma is a solid mass of Aspergillus hyphae, mucus, fibrin, and other cellular debris, formed inside a pre-existing area of pulmonary cavity or scar. Patent expiration of branded products and drug resistance to antifungal medications are the factors restraining growth of the market. Moreover, antifungals can also cause serious side effects such as liver and kidney damage.

Aspergillosis Treatment Market Regional Insights

Regional segmentation of Aspergillosis treatment market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America Aspergillosis treatment market is expected to hold a dominant position, due to increasing government initiatives for diagnosing and treatment of infection. In 2016, the Infectious Diseases Society of America (IDSA) published new guidelines for the diagnosis and treatment of infections due to Aspergillus species. The document offers guidance on non-culture-based identification of Aspergillus infections and dejects the use of combination anti-fungal therapy for primary management. The guidelines also define therapy of isavuconazole, a new U.S. FDA approved anti-fungal drug in March 2015 to treat mucormycosis and aspergillosis. Asia pacific Aspergillosis treatment market share is expected to witness significant growth during the forecast period, owing to large volume of untreated patients. Many countries in the region lack resources for suitable infection diagnostics and control. Opportunistic invasive fungal infections (IFIs) have a substantial impact on public health in the region, which requires early diagnosis and suitable treatment. The occurrence of IFI in the Asia Pacific region is increasing due to increased population of immunosuppressed patients resulting from transplantation and treatments for cancer, as well as the impact of HIV.

Aspergillosis Treatment Market Competitive Analysis

Major players operating in the aspergillosis treatment market include Abbott laboratories, AstraZeneca plc, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson Services, Inc., Mylan Pharmaceuticals, Inc., Novartis AG, Pfizer, Inc., and Takeda Pharmaceutical Company Ltd.

Get Table Of Content:

https://www.coherentmarketinsights.com/ongoing-insight/toc/1587

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:sales@coherentmarketinsights.com

Visit our news Website: www.coherenttimes.org

[maheshposts-blog1]

Growing Demand for Propelling the Antifungal Drugs Market: China Product Intelligence Market 2021

Albany/New York Pune/India, April, 2017.

Marketresearchdata.net has added a new report on China Antifungal Drugs Market. The report predicts the market size of China Antifungal Drugs Market is expected to reach XX billion by 2021.

The report covers the analysis of global as well as regional markets of China Antifungal Drugs Market. Moreover, the report gives insights into the factors that affect the global as well as regional performance of the market in the short run and in the long run.

Antifungal drugs are used to cure fungal infections which are usually caused by unclean, unhygienic and damp environment. Fungal infections are the invasion of epithelial tissue by microscopic organisms. Systemic fungal infections are caused by the indigestion or inhalation of fungus spores and cause fungal pneumonia and opportunistic fungus causes diseases like candidaisis, meningitis, mucormycosis, etc. Most of the fungal infections and fungal diseases are generally non-lethal but they are very uncomfortable to live with. Commonly occurring fungal infections are responsible for the rise of antifungal drugs market. Antifungal drugs work through various mechanisms such as by inhibiting cell wall formation, cell membrane disruption and cell division. The antifungal drugs market is segmented by drug type into Echinocandins, Azoles, Polyenes, Allylamines and Other Drugs. Polyenes are further classified into Amphotericin B, Nystatin and Natamycin. Based on the type of therapeutic indications it is segmented into Aspergillosis, Dermatophytosis, Candidiasis, Other therapeutic indications. Also, the market is segmented by applications into Powders, Ointments, Drugs, and Pastes.

Browse full Report visit:

http://marketresearchdata.net/Reports/china-antifungal-drugs-market

The major factors driving the market are increase in susceptible immune compromised patient population and rising incidences of fungal infections along with government and corporate investments to tackle the issues. However, there are some road blocks like increase of drug resistant strains, challenges in anti-fungal drug development and presence of generics. Nevertheless, the market has lucrative opportuntis in the form of Limited effective Therapeuti options, increasing disposable per-capita income if manufacturers can overcome challenges like growing resistance to anti-fungal drugs and usage of traditional alternatives. The China Antifungal Drugs Market is estimated at $XX million in 2016 and is poised to be growing at a CAGR of XX%, to reach $XX million by 2021. XXXXXXXX is the largest segment where as XXXXXXX is showing a promising growth in the region in the given forecast period of 2016-2021.

Table of Content

1. Introduction   1.1 Market Definition 1.2 Study Deliverables 1.3 Base Currency, Base Year and Forecast Periods 1.4 General Study Assumptions

2. Research Methodology   2.1 Introduction   2.2 Research Phases    2.2.1 Secondary Research  2.2.2 Primary Research  2.2.3 Econometric Modelling  2.2.4 Expert Validation 2.3 Analysis Design   2.4 Study Timeline

3. Overview   3.1 Anti-Fungals Classification 3.2 Epidemiology    3.2.1 Aspergillosis  3.2.2 Candida Species Infections  3.2.3 Dermatophytosis

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC) 4.1 Market Drivers    4.1.1 Increase in susceptible immune compromised patient population  4.1.2 Increasing incidence of fungal infections  4.1.3 Increasing government and Corporate Funding 4.2 Market Restraints  4.2.1 Increasing drug resistance strains   4.2.2 Challenges in antifungal drug development  4.2.3 Presence of Generics and alternative therapies 4.3 Key Challenges    4.3.1 Limited Effective Therapeutic Options  4.3.2 Oppurtunities for New Drugs  4.3.3 Increasing Disposable income Percapita 4.4 Current Opportunities in the Market  4.4.1 Growing resistance to antifungal drugs  4.4.2 Use of traditional medicines to control fungus

5. Market Segmentation   5.1 Introduction   5.2 China Antifungal Drugs Market, By Product Type  5.2.1 Introduction  5.2.2 Azoles   5.2.2.1 Introduction   5.2.2.2 Flucanazoles   5.2.2.3 Itraconazoles   5.2.2.4 Clotrimazoles   5.2.2.5 Other Azoles  5.2.3 Allylamines   5.2.3.1 Introduction   5.2.3.2 Terbinafine   5.2.3.3 Naftifine   5.2.3.4 Other Allylamines  5.2.4 Echinocandins   5.2.4.1 Introduction   5.2.4.2 Capsofungin   5.2.4.3 Micafungin   5.2.4.4 Other Echinocandins  5.2.5 Ployenes   5.2.5.1 Introduction   5.2.5.2 Amphotericin B   5.2.5.3 Nystatin   5.2.5.4 Natamycin  5.2.6 Others 5.3 China Antifungal Drugs Market, By Dosage Form  5.3.1 Introduction  5.3.5 Solutions   5.3.5.1 Y-O-Y Growth Rate   5.3.5.2 Pricing  5.3.3 Tablets & Capsules   5.3.3.1 Y-O-Y Growth Rate   5.3.3.2 Pricing  5.3.4 Ointments & Creams   5.3.4.1 Y-O-Y Growth Rate   5.3.4.2 Pricing  5.3.5 Powders   5.3.5.1 Y-O-Y Growth Rate   5.3.5.2 Pricing  5.3.6 Others 5.4 China Antifungal Drugs Market, By Applications  5.4.1 Introduction  5.4.2 Aspergillosis  5.4.3 Candidiasis  5.4.4 Dermatophytosis  5.4.5 Other Fungal Diseases

To make an enquiry about report visit:

http://marketresearchdata.net/Reports/MakeEnquiryRequest/17434.html

Reasons to buy this report: 1) Deep insights and comprehensive analysis of global and regional markets 2) complete coverage of key product types and application segments and their sub-segments through geographies and world market 3) Deep dive into the market share and recent developments of the key players in the industry. 4) Analysis and presentation of evolving market trends, patterns, technological advancements 5) Presentation of market dynamics and factors bearing control over the global and regional markets. 6) Competitive landscapes and insights 7) Opportunity mapping in terms of product developments, research and developments and technological advancements.

To know more about us Visit:   http://marketresearchdata.net/Welcome/About.html Reasons to choose marketresearchdata.net 1) 24X7 sales support and free analyst time for post purchase queries. 2) Exclusive support from the analysts and industry experts possessing experience over 5 years in the industry 3) Long term relationship management and exclusivity benefits for our clients

To make sample request for report visit: http://marketresearchdata.net/Reports/MakeSampleRequest/17434.html Contact Us: USA/Canada Toll Free: +18006380796 Rest of the World: +919765091631 Email: sales@marketresearchdata.net website: www.marketresearchdata.net

[sapanas]

Mucormycosis Market 2019: Global Analysis, Business Strategy, Development Status, Emerging Technologies, Future Plans And Trends By Forecast 2023

Mucormycosis Market – Overview

The rise in the causative factor for mucormycosis and poor detection rate has contributed to the development of the Mucormycosis Market. Reports that gauge the healthcare industry have been made available by Market Research Future which creates reports on several industry verticals that review the market growth and prospects. The market is expected to garner a CAGR of 7.3% approx, in the upcoming period.

The declining overall health and well-being standards globally have induced the development of the mucormycosis market. Also, most of the population base affected by mucormycosis has a low immunity level and a limited tolerance level to the treatments that are subsequently administered. The market is expected to gain traction in the upcoming period due to the increasing incidence of immunological diseases around the world.

Avail Free Sample Copy at https://www.marketresearchfuture.com/sample_request/5440

Segmental Analysis

The segmental analysis of the mucormycosis is carried out on the basis of diagnosis, species, treatment, region, and end-users. Based on the species, the mucormycosis market is segmented into Rhizomucor, Rhizopus, Apophysomyces, Cunninghamella, Lichtheimia, Saksenaea, and Mucor, and others. Based on the diagnosis, the mucormycosis market is segmented into Magnetic resonance imaging (MRI), Computed Tomography (CT), tissue biopsy, and others. The segmentation of the mucormycosis market by treatment comprises of antifungal drugs, surgery, amphotericin B therapy, and others. The end-user segmentation of the mucormycosis market comprises of medical institutes, hospitals & clinics, research organization, and others. By regions, the mucormycosis market consists of Europe, the Americas, Asia Pacific, and the Middle East and Africa.

Detailed Regional Analysis    

The regional evaluation of the mucormycosis market covers regions namely Europe, the Americas, Asia Pacific, and the Middle East and Africa. The Americas region dominates the mucormycosis market due to a strong healthcare sector and the presence of an immense patient population for mucormycosis. Due to the scarcity of limited oral preparation in the market, the progress and licensing of new drugs in the market is a big opening for the advance of the market throughout the forecasted period. The European region is the subsequent major market for mucormycosis due to the development in the technology of surgical devices along with the increasing incidence of fungal infections among the patients. The rising percentage of diabetes mellitus population mostly in the developed countries of the European region is anticipated to open up new prospects for the mucormycosis market. The Asia Pacific region is the top mounting region for antifungal treatment owing to the growing prevalence of HIV and the presence of vast untapped growth chances for the expansion of the market.

Competitive Analysis

The advancement of the market is projected to capture amplified impetus in the coming years chiefly due to the incidence of contributory government plans. The escalated turnaround in the market is likely to set off new openings for the development of the market. The enhancement in different domestic economies is projected to encourage the progress of the market in the impending period. The ease in accessing key planned opportunities important to consequent stabilization of inflation is projected to generate a promising option for development in the approaching years. In the approaching years, the control exerted by fairly high-income level nations around the world and the likely gains observed towards a few of the currencies around the world is projected to strengthen the fruition of the market in the forecast period. A significant climb in the number of backers in the market is expected to craft an advantageous state of affairs for the evolution of the market in the projected period.

Browse Complete Report with TOC at https://www.marketresearchfuture.com/reports/mucormycosis-market-5440

The significant competitors in the mucormycosis market are Biocon Limited (India),  Cadila Pharmaceuticals Limited (India), Novartis AG (Switerzland), Abbott Laboratories (U.S.), Myers Squibb (U.S.),  F. Hoffman La Roche (Switerzland),   Merck Sharp and Dohme (U.S.), Sanofi (France), Mylan Labs (U.S.), Johnson & Johnson (U.S.), Bristol Bayer AG (Germany), Lonza Group (Switerzland), Pfizer Inc. (U.S.), Gilead Sciences (U.S.), and others.